(MedPage Today) — CHICAGO — First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer, according to the DESTINY-Breast09…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115844
Author :
Publish date : 2025-06-02 12:00:00
Copyright for syndicated content belongs to the linked Source.
